NCT03247790

A Study of Lasmiditan in Participants With Migraine

An Open-Label, Two-Period Study to Evaluate the Pharmacokinetics of Lasmiditan in Migraineurs During Acute Migraine Attacks and During Inter-Ictal Periods

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks. Information about any side effects that may occur will also be collected. This study includes two study periods. Each study period requires an overnight stay in the Clinical Research Unit (CRU) for at least one night (and up to three nights), followed by up to two outpatient appointments. This study will last approximately 5-6 weeks (not including screening). Follow-up is required four to seven days after last dose of investigational drug. Screening is required within 28 days prior to the start of the study. This study is for research purposes only and is not intended to treat any medical condition.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	Lasmiditan	Administered orally

Timeline

• Start date: 2017-08-16
• Primary completion: 2018-01-15
• Completion: 2018-01-15
• First posted: 2017-08-14
• Last updated: 2019-12-02
• Results posted: 2019-12-02

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study